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Background: The COSMIC trial is designed to evaluate toxicity in dose-escalated treatment with
intensity-modulated radiotherapy (IMRT) and carbon ion boost for malignant salivary gland tumors (MSGT) of the
head and neck including patients with inoperable/ incompletely resected MSGTs (R2-group) and completely
resected tumors plus involved margins or perineural spread (R1-group).
Methods: COSMIC is a prospective phase II trial of IMRT (25 × 2 Gy) and carbon ion boost (8 × 3 GyE). Primary
endpoint is mucositis CTC°III, secondary endpoints are local control, progression-free survival, and toxicity. Evaluation
of disease response is carried out according to the Response Evaluation Criteria in Solid Tumors (RECIST); toxicity is
assessed using NCI CTC v 3.0.
Results: Twenty-nine patients were recruited from 07/2010 to 04/2011, all patients have at least completed first
follow-up. Sixteen patients were treated in the R2-group, 13 in the R1-group. All treatments were completed as
planned and well tolerated, mucositis CTC grade III was 25% (R2) and 15.4% (R1), no dysphagia CTC grade III was
observed, no feeding tubes were necessary. Side-effects rapidly resolved, only 4 patients (13.8%) reported
xerostomia grade II at first follow-up. Overall response rate (complete and partial response) according to RECIST in
the R2-group is 68.8% at 6–8 weeks post treatment, all patients within this group showed radiological signs of
treatment response.
Conclusion: No unexpected toxicity was observed, mucositis rates and other side effects do not differ between
patients with visible residual tumor and macroscopically completely resected tumors. Initial treatment response is
promising though longer follow-up is needed to assess local control.
Trial registration: Clinical trial identifier NCT 01154270Background
Local control for malignant salivary gland tumors
(MSGT) remains a challenge.
While high-precision techniques such as intensity-
modulated radiotherapy (IMRT) and fractionated stereo-
tactic radiotherapy (FSRT) could already improve local
control as compared to conventional RT techniques and
achieve 3-year PFS rates around 38% [1], significant
improvements were only seen by application of particle
therapy. So far, the highest local control rates at 75 – 100%
[2,3] were achieved by neutron radiation albeit at the cost
of significant late toxicity. Heavy ion therapy using carbon* Correspondence: alexandra.Jensen@med.uni-heidelberg.de
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reproduction in any medium, provided the orions however, so far only showed a mild toxicity profile
even in dose escalation and hypofractionation [4].
The German carbon ion pilot project succeeded to
establish a mixed beam regimen consisting of intensity-
modulated radiotherapy (IMRT) and carbon ion boost
for adenoid cystic carcinoma: with 78% at 4 years, local
control rates were in the range of results formerly
achieved by neutron therapy but without the dreaded
late toxicity [5]. A recent update of all patients with ade-
noid cystic carcinoma treated with this regimen between
1997 and 2008 supports these findings with consistently
low treatment-related side effects [6]. These results in
turn led to the acceptance of this regimen as the stand-
ard treatment and method of choice for adenoid cystic
carcinoma in Germany.
Doses recommended for treatment of malignant sali-
vary gland tumors are high [7-9], due to the possibilityLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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particle therapy does offer the promise of improved
results for all types of malignant salivary gland cancers
whether in the definitive or adjuvant setting.
Whereas the initial carbon ion project only included
patients with inoperable or incompletely resected adenoid
cystic carcinoma, the COSMIC trial was designed to inves-
tigate efficacy and toxicity of combination therapy as
IMRT plus carbon ion boost also for all types of MSGTs as
well as macroscopically completely resected tumors with
risk factors such as R1-resections or perineural spread. As
patient accrual is much faster than expected in this rare
disease an interim analysis seems warranted.
Methods
Patients
Patients with pathologically confirmed malignant salivary
gland tumor of the head and neck are eligible for this trial.
Patients may be inoperable and receive treatment as
definitive radiotherapy or have received surgery for their
primary tumor with either macroscopic (R2) or micro-
scopic (R1) residue and/ or perineural invasion. Age
between 18 and 80 years, Karnofsky performance score
of >70% were also required. Exclusion criteria were prior
chemotherapy or radiotherapy [10].
Work-up included complete panendoscopy, diagnostic
CT scans of the neck and chest and abdominal ultra-
sound. In the absence of contraindications, all patients
receive diagnostic MRI scans for treatment planning and
follow-up.
The trial was reviewed and approved by the University
of Heidelberg Medical School Ethics Committee; informed
consent is obtained from all patients prior to inclusion.
Radiotherapy
Immobilisation/ planning examinations
Patients are immobilized using individual thermoplastic
head masks incl. shoulder fixation (HeadStepW, ITV).
Planning examinations consist of a planning CT scan
(3 mm slice thickness) with the patient positioned in the
individual fixation device and contrast-enhanced MRI for
3D image correlation.
Target volumes/ dose prescription and constraints
CTV1 (carbon ion boost) includes the macroscopic
tumour/ prior tumour bed with special focus on the
R1-area as well as respective neural pathways to the base
of skull. For tumors of the parotid gland, the whole former
parotid area is also included in the CTV1. In order to
avoid potential late effects, the mandibular joint is kept
outside the CTV1 whenever reasonably possible. PTV1
consists of a 3 mm margin around the CTV1 but does not
extend into critical organs at risk (i.e. brain stem, spinal
cord). Twenty-four GyE carbon ions in 3 GyE per fraction(5 fractions per week) are prescribed to the CTV1 as an
upfront boost, the CTV1 should be covered with the 95%
prescription isodose.
CTV2 includes CTV1 with safety margins along typical
pathways of spread. Only ipsilateral nodal levels (II and III)
are included, however, in case the primary tumour is
located at or crossing midline, these are bilaterally
included. In case of nodal metastases, additional nodal
levels are covered as indicated. CTV2 needs to encompass
the complete surgical operational area and accounts for
set-up variations, hence corresponds to the PTV2
(CTV2=PTV2). Should the primary tumour be located
within the parotid gland, also the parotid duct needs to be
within the CTV2. The CTV2 is prescribed 50 Gy IMRT in
25 fractions (5 fractions per week), coverage with at least
the 90% prescription isodose needs to be aimed for.
Summation plans are evaluated according to the follow-
ing criteria: < 20% of the CTV1 should receive≥ 110% of
the prescribed dose, <5% of CTV1 or CTV2 should
receive≤ 90% of the prescribed dose, and <2% or 2 cc of
tissue outside the CTVs should receive≥ 110% of the
prescribed dose to the CTV1. In addition, the following
normal tissue constraints were used in evaluation of the
summation plan (carbon ion and photon IMRT) plan at
standard fractionation (2 Gy/ fraction).
 Spinal cord: the dose to any point within the spinal
cord should not exceed 50 Gy to any volume larger
than 0.03 cc.
 Brain stem: the tolerated dose is 54 Gy; maximum
tolerated dose in volumes of ≤ 1 cc : 60 Gy.
 Optic chiasm/ optic nerves: maximum dose to these
structures should be ≤54 Gy, in case this dose limit
cannot be kept without compromising target volume
coverage, these issues were discussed with the
patient and decisions made accordingly.
 Eyes: maximum doses ≤45 Gy to the posterior bulb/
retina; doses to the whole eye were reduced as low
as reasonably achievable without compromising
target volume coverage
 Parotid glands: mean dose to at least one gland
below 26 Gy; alternatively at least 20 cc of the
combined volume of both parotid glands to< 20 Gy
or at least 50% of one gland to <30 Gy.
Treatment planning and radiotherapy
Carbon ion therapy
Carbon ion therapy is given at the HIT (Heidelberg ion
therapy centre) after inverse treatment planning in active
beam application (raster-scanning method) [11]. The PTV
is divided into iso-energetic slices roughly corresponding
to their radiological depths. The raster-scanning method
uses mono-energetic carbon ion beams, which are extracted
from the accelerator system (synchrotron) and magnetically
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Using this method, almost any desired dose distribution can
be created and dose to surrounding critical structures can
be minimized.
Inverse treatment planning is carried out on a dedi-
cated Siemens treatment planning system (TPSW). Due
to increased biological effective dose of ion beams TPSW
additionally includes methods for inverse treatment
planning and biological RT treatment optimization for
particle therapy.
Daily image guidance consists of orthogonal x-ray
controls in treatment position with robot-mounted x-ray
tubes/ receptors. After acquisition of orthogonal x-rays, the
automatic 2D-3D pre-match is carried out (Siemens syngo
PT treatment) and verified by the radiotherapist/radiation
oncologist. Manual adjustment of the match can be carried
out on-line and the resulting correction vector, including
rotations, is subsequently applied to the patient position.
Patient position is controlled at each session and shifts are
always corrected using a robot-mounted treatment table
allowing position correction in six degrees of freedom.
IMRT
IMRT is given at the Dept of Radiation Oncology in 25
fractions (5 fractions per week) either on a dedicated 6 MV
tomotherapy unit or on a 6 MV linear accelerator in step
and shoot technique after inverse planning either with the
optimization tool KonRad MRCW (Siemens OCS) or the
dedicated tomotherapy inverse planning software. In both
cases, regular image guidance is carried out. If necessary,
daily pretreatment online correction of translational vectors
is applied. Total doses take account of the doses applied by
daily image guidance with MV-cone-beam CT. Standard
3D treatment was not allowed within the protocol.
Follow-up
Regular follow up is carried out 6 weeks post treatment,
3 months (4–5 months post completion of therapy)
thereafter, and then in 6 monthly intervals including
fibreoptic examination and local imaging with MRI.
Study design and analysis
COSMIC is a prospective, mono-centric phase II trial
evaluating acute mucositis ≥CTC°3 as the primary end-
point. Planned accrual is 54 patients.
Secondary endpoints are local control (LC), progression-
free survival (DFS), and toxicity (acute and late radiation
effects). Toxicity is assessed using NCI CTC v 3.0 at treat-
ment completion as well as at each follow-up visit.
Evaluation of disease response is carried out according to
the Response Evaluation Criteria in Solid Tumors (RECIST)
[12] 6 weeks, 4–5 months, 6–7 months post completion of
treatment and then in 6-monthly intervals. Further details
can be found in the published trial protocol [10].Results
Between July 2010 and April 2011, twenty-nine patients
were accrued to the COSMIC trial. No patient was
excluded or had to discontinue therapy. All patients
completed treatment as scheduled.
Thirteen patients with macroscopically complete resec-
tions (group R1) and 16 patients with either incomplete
resection (7 pts) or inoperable tumors (9 pts) (group R2)
were included. Median age was similar in both groups:
56 years (R2) and 55 years (R1). Most patients had ade-
noid cystic carcinoma (R2: 16/16 pts, R1: 8/13 pts) and
only 5 patients in the R1-group had other histologies.
The R2 group included a high number of MSGTs in the
paranasal sinus, whereas there was a higher proportion
of MSGTs of the large salivary glands in the R1-group.
While many patients in the R2-group had very advanced
disease (T4: 11 pts), tumor extent in the R1-group
tended to be smaller (T4: 6 pts). For one patient in
the R2-group a valid TNM staging for tumors of the
external auditory canal does not exist, for two patients in
the R1-group the pathological TNM stage is unknown.
Three patients in the R2 group had known pulmonary
metastases at presentation; none of the resected patients
in R1 had distant metastases. Details of patients’ baseline
characteristics can be found in Table 1.
In all cases, treatment dose could be applied according
to protocol (Table 2) and dose prescription recommen-
dations (<5% of CTV1 or 2 receiving less than 90% of
the dose prescribed) were met in all patients. While
CTV2 volumes are comparable in both groups, median
CTV1 volume is much larger in the R2 group. The pro-
portion of patients requiring more complex planning
procedures such as intensity-modulated particle therapy
(IMPT) remains essentially the same in both groups,
while more patients in the R2 group underwent
tomotherapy rather than step-and-shoot IMRT and more
patients (R2: 6 pts; R1: 2 pts) underwent bilateral nodal
irradiation in the R2 group (Table 2).
Treatment tolerance and toxicity
Treatment was well tolerated although treatment includ-
ing set-up, position verification, and irradiation for carbon
ions takes between 30 and 45 min.
Treatment-related acute effects as assessed at comple-
tion of radiotherapy were generally mild with mucositis
CTC °III occurring in 25% (R2) and 15.4% (R1). Despite
comparatively extensive treatment fields, only mild xeros-
tomia was observed; at completion of treatment, rates of
xerostomia CTC°II were 15.4% in the R1 group and none
in the R2 group. Almost all (100% in R2 and 84.6% in R1)
reported severe to complete loss of taste by the end of
treatment leading to weight loss in 81.3% (R2) and 69.2%
(R1) of patients. There was no higher-grade dysphagia,
only few patients (R1: 15.4%) reported dysphagia CTC°II.





Patient number 16 13
Prior surgery 7 13
Recurrent tumors 3 2
Median age (years) 56 55












Adenoid cystic carcinoma 16 8
Mucoepidermoid carcinoma 0 3
Adenocarcinoma 0 1
Squamous cell carcinoma 0 1
Site
Base of skull 0 1
Paranasal sinus 7 3
Palate 0 1
Nasopharynx 3 0
External auditory canal 1 0
Parotid gland 3 2
Submandibular gland 1 4
Lacrimal gland 1 1
Lacrimal duct 0 1










C12 23.81 23.87 23.83
IMRT 50.74 50.42 50.6
C12 optimization
technique
IMPT (pts) 11 9 20
SBO (pts) 5 4 9
IMRT technique
step& shoot IMRT 10 12 22
Tomotherapy 6 1 7
Treatment
volumes (ml)
CTV1 167.1 94.13 138.38
CTV1 range 161.95 - 618.5 48.66 - 187.82 32.56 - 390.6
CTV2 466.73 413.2 431.5
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due to dysgeusia and subsequent loss of appetite, we found
a median weight loss of 5 kg (R2) and 5.5 kg (R1) in our
patient cohort. Two patients in the R2 group and one
patient in the R1 group showed reduced jaw opening prior
to and at completion of therapy: one patient improved
under therapy due to tumor regression. Roughly 37.5% of
patients in R2 developed middle ear effusions during ther-
apy and only 15.4% in R1.
Symptoms rapidly resolved after treatment, only one
patient in the R2-group showed mucositis CTC°I at first
follow-up (6–8 weeks post completion of treatment),
otherwise there was no case of residual mucositis. Xeros-
tomia was reported at an overall rate (CTC°I/II) in
75% (R2) and 84.6% (R1), only 12.5% of patients in theR2-group reported mild swallowing difficulties on their
first follow-up appointment. All patients reported
improvement of dysgeusia with dysgeusia slowly resolv-
ing with time and leading to further weight loss post
completion of treatment in 18.8% (R2) and 30.8% (R1)
(Table 3). However, body weight had stabilized in all of
these patients on their first follow-up.Treatment response
Overall local response rate (complete and partial remis-
sions) 6–8 weeks after completion of treatment in the R2
group is 68.8% (CR: 2/16 pts, PR: 9/16 pts, SD: 5/16 pts)
according to RECIST. However, all of the patients showed
signs of tumor response such as reduced contrast-en-
hancement on MRI, carbon ion dose distribution, initial
and follow-up MRI scans of a patient with good PR is
shown in Figures 1, 2, 3, 4. With our median follow up of
3 months [range 3–12 months], one of the partial remis-
sions has already developed into a complete remission
6 months post treatment.
One patient with adenoid cystic carcinoma and pul-
monary metastases in the R2-group unfortunately
showed a very good locoregional PR but distant disease
progression and is currently undergoing palliative
chemotherapy. There was no other case of disease pro-
gression in either the R2 or the R1 group.
Table 3 Adverse events
R2: visible residual tumor R1: R1/ Pn+ resected tumors
end of RT 1st f/u end of RT 1st f/u
Mucositis I 3 (18.8%) 1 (6.3%) 4 (30.8%) 0
II 7 (43.8%) 0 6 (46.2%) 0
III 4 (25%) 0 2 (15.4%) 0
Dermatitis I 13 (81.3%) 0 12 (92.3%) 1 (7.7%)
II 2 (12.5%) 0 0 0
III 1 (6.3%) 0 1 (7.7%) 0
Xerostomia I 7 (43.8%) 10 (62.5%) 6 (46.2%) 11 (84.6%)
II 0 2 (12.5%) 2 (15.4%) 0
Dysphagia I 7 (43.8%) 2 (12.5%) 4 (30.8%) 0
II 0 0 2 (15.4%) 0
III 0 0 0 0
Weight loss yes 13 (81.3%) 3 (18.8%) 9 (69.2%) 4 (30.8%)
kg median 5 5,5
min 3 5
max 10 12
Feeding tube 0 0 0 0
Loss of taste 16 (100%) 0 11 (84.6%) 0
Middle ear effusion 6 (37.5%) 5 (31.3%) 2 (15.4%) 2 (15.4%)
Otitis 0 0 0 0
Paralysis of facial nerve 1 (6.3%) 1 (6.3%) 1 (7.7%) 1 (7.7%)
Ptosis 1 (6.3%) 1 (6.3%) 0 0
Reduced jaw opening 2 (12.5%) 2 (12.5%) 1 (7.7%) 1 (7.7%)
Xerophthalmia 0 1 (6.3%) 1 (7.7%) 0
Conjunctivitis 1 (6.3%) 0 0 0
Lymph edema 1 (6.3%) 1 (6.3%) 0 2 (15.4%)
Hearing impairment 2 (12.5%) 0 0 0
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Introduction of high precision radiotherapy and particle
therapy has changed patients prognosis in this rare condi-
tion. Neutron radiotherapy was able to achieve high local
control rates in the past [2,13,14], the RTOG-MRC rando-
mized trial reported a 67% local control in the neutron
group as opposed to 17% in the photon group in unresect-
able MSGTs [13]. However, this treatment was often
accompanied by significant side effects such as temporal
lobe necrosis, ulceration, spinal cord myelopathy, and loss
of vision due to optic neuropathy, retinopathy, acute angle
glaucoma and bleeding [2,14]. Severe long-term effects
were reported in more than 14% of patients [2].
Recent results in charged particle therapy produced
much more favorable toxicity profiles even though hypo-
fractionated, dose-escalated regimen were used [4-6,15].
No CTC°III late toxicities and very few °III acute reactions
occurred in the Japanese treatment regimen published by
Mizoe et al applying 70.2 GyE (3× 3.9 GyE/wk) or 64 GyE(4 × 4 GyE/ wk) [4]. Including various histological subtypes
of MSGTs, local control at 5 years was 100%. Pommier et al.
[15] treated 23 patients with adenoid cystic carcinoma with
protons at 75.9 GyE (median) in various fractionation
schemes. Overall local control at 5 years was 93%, however,
there was one °V late toxicity (temporal lobe necrosis).
IMRT (54 Gy) plus carbon ion boost (18 GyE à 3 GyE)
at a biologically equivalent dose of roughly 77 Gy for ade-
noid cystic carcinoma however, also achieved impressive
results without any higher-grade (CTC°III or higher) late
toxicity resulting in local control rates of 78% in 4 years [5]
with a recent update confirming these results [6]. Predom-
inant site of relapse in this cohort is still in-field or within
the dose gradient to adjacent organs at risk despite relative
already high radiation doses. Based on this experience,
COSMIC includes a further dose escalation mainly of the
carbon ion part to 24 GyE (à 3 GyE per fraction) and
IMRT to 50 Gy corresponding to a biologically equivalent
dose of approximately 80 Gy with the aim to further
Figure 1 51 year old patient with adenoid cystic carcinoma
extending from the right maxillary sinus into the right orbit
and cavernous sinus, contrast-enhanced, T1-weighted MRI for
treatment planning.
Figure 2 Axial carbon ion dose distribution (orbit/ cavernous
sinus), 3-field IMPT, 100% corresponding to 24 GyE carbon
ions.
Figure 3 Coronal carbon ion dose distribution, 3-field IMPT,
100% corresponding to 24 GyE carbon ions.
Figure 4 51 year old patient with adenoid cystic carcinoma,
contrast-enhanced, T1-weighted MRI at first follow-up showing
partial remission but highly reduced contrast-enhancement.
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the first trial to include patients without visible residual
tumor. Hence potential side effects may be increased.
COSMIC is also recruiting uncommonly fast in this very
rare disease, therefore an interim analysis to exclude unex-
pected higher-grade toxicity is necessary.
Toxicity
To present, no unexpected acute toxicity has occurred in
the COSMIC patients with transient alteration of taste,
mild xerostomia, and dysphagia being the most frequently
reported. Also, we found no higher grade (CTC°III or
higher) acute toxicity which is in good agreement with
other charged particle therapy series [4,5,15].
Treatment volumes tended to be large (CTV1:
138.38 ml, CTV2: 431.5 ml), even though, there was no
case of CTC°III dysphagia and only 6/29 patients with
mucositis CTC°III (20.7%; R2: 25%, R1: 15.38%). Patients
in the R1 group did not show a higher percentage of
grade III mucositis as compared to patients with visible
residual disease. Although mucositis CTC°III was
reported in only 6% of patients in our previous series
[5,16], however, this series predominantly included
tumors located at the base of skull, no patients with
tumors of the major salivary glands were included.
Mucositis rates in the Japanese series were also compara-
tively low, but target volumes also tended to be much
smaller [4]. R1-resected tumors not including the skull
base were not included in both cohorts [4,5]. In view of
treated anatomical sites, occurrence of CTC °III mucosi-
tis at roughly 20% is still low especially considering the
fact that our cohort included 10 patients with tumors of
the major salivary glands and 10 patients with extensive
tumors of the paranasal sinuses.
Perineural infiltration and skip lesions are significant,
independent predictors of local control in most series for
MSGTs [7,8,17,18], therefore our policy is to include
potentially involved neural tracts up until their entrance
into the skull base as proposed by Garden et al [8]. For
the facial nerve, this brings higher dose close to the mid-
dle ear therefore, the occurrence of middle ear effusions
in 8/29 patients (27.6%) is not surprising. In all cases,
these symptoms were at least improving at first follow-
up and are therefore acceptable.
Efficacy
Follow-up is yet too short to analyze efficacy in the R1
group. However, response rates and extent of response in
the R2 group are promising: overall response (CR and PR)
was 68.8% with 2/16 pts showing complete remissions
according to RECIST at the first follow-up. All of the
patients in the R2 group showed significantly reduced con-
trast-enhancement on their follow-up MRI. Very little data
has been published on response rates and timeline ofresponse in MSGTs. Our own experience suggests high re-
sponse rates of patients with adenoid cystic carcinoma
with the tumor slowly regressing and disappearing within
time spans between 6–12 months. Data from the neutron
era report tumor clearance rates of up to 84.6% (11/13 pts)
but does not mention time intervals [13]. The authors do
see a correlation between tumor response and long-term
local control, therefore our response rates at a median fol-
low-up of 3 months seems promising.
Some limitations of the trial have shown up in this in-
terim analysis:
Approximately 13 of 29 patients underwent macroscopic-
ally complete resections and exhibit risk factors such as
involved margins or perineural spread (R1), and 16/29
patients still had visible residual tumor (R2), the two
cohorts are comparable in a first approximation. However,
COSMIC should include various types of MSGTs in order
to establish the carbon ion combination regimen for MSGT
histologies other than adenoid cystic carcinoma. Most
patients recruited so far were diagnosed with adenoid cystic
carcinoma, further investigations need to exclude adenoid
cystic carcinoma from the trial to address this issue.
Dose-escalated combination treatment may hopefully
lead to even higher local control rates, however, none
of the local treatment regimens has yet had an impact
on overall survival or distant metastasis-free survival in
malignant salivary gland tumors [5,7,8,19]. The use of
concomitant chemotherapy or immunotherapy in squa-
mous cell carcinoma of the head and neck (SCCHN)
[20,21] has led to a significant improvement not only in
local control but also in overall survival. Radioche-
motherapy in treatment of malignant salivary gland
tumors however, has not evolved beyond the phase II-stage
or retrospective analysis of very heterogeneous treatment
regimen [22-24] into a treatment standard so far.
Hence another questions remains: patients with adenoid
cystic carcinoma may also benefit from combined treat-
ment with i.e. new substances such as EGFR-inhibitors in
terms of local and distant control [25]. However, to our
knowledge, there is no prospective clinical trial evaluating
combination treatment of any substance with carbon ion
therapy, hence we will shortly commence a phase-II trial
with the EGFR-receptor antibody cetuximab addressing
this issue [26].
Conclusion
There is no unexpected toxicity in the COSMIC trial,
mucositis rates and other side effects do not seem to differ
in the patients without visible residual tumors (R1 group).
Initial treatment response of the dose-escalated regimen
is promising. In view of a median follow-up of 3 months
in our patients, longer follow-up is needed to assess
secondary trial endpoints such as local control and pro-
gression-free survival.
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